Tag Archives: pharmaceutical costs
Prior Authorizations: Proportionate measure or burden without benefit?
Pamela White advocates for strong consumer protection regulation of health insurance company use of prior authorizations.
L’intelligence artificielle du point de vue de la santé globale
Vincent Couture et Jean-Christophe Bélisle-Pipon explorent les nouvelles menaces existentielles qu’engendre l’intelligence artificielle restreinte et générale pour la santé mondiale et proposent des stratégies pour s’y attaquer.
Mind the Ethical Gap in AI-Powered Drug Discovery
Dessislava Fessenko shows that while artificial intelligence might revolutionize drug development, its use comes with risks and potential ethical implications. Iterative ethics oversight from the get-go is needed to address the looming concerns.
Monopolies on New Medicines & Trade with the U.S.
Deborah Gleeson and Ronald Labonté object to lengthening market exclusivity for biologic medicines in the United States-Mexico-Canada Agreement.
Pharmacare: Improving Access to Expensive Drugs
Marc-André Gagnon dispels misconceptions about the benefits of private health insurance plans and argues in favour of a universal model for pharmacare.
Impact Ethics 